Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
OSRH vs IBO: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
IBO Wins Head-to-Head Institutional Verdict (2–1 across 6 Pillars · 7–2 Matrix Metrics)
IBO Overall Winner
6-Pillar Tally: OSRH 1 – 2 IBO (3 Tie)
Matrix Metrics: OSRH 2 – 7 IBO
As of Nov 16, 2026, Impact BioMedical, Inc. (IBO) is the stronger overall head-to-head candidate over OSR Holdings, Inc. (OSRH) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow). OSRH carries a Unified Composite Score of 45.0/100 (HOLD) at $0.12 (N/M Forward P/E, -960.8% operating margin), whereas IBO carries 36.8/100 (SELL) at $4.91 (N/M Forward P/E, -12621.0% operating margin).
- Composite vs. Pillar Nuance: While OSRH currently prints a higher short-term Unified Composite Score (45.0/100 HOLD vs. IBO 36.8/100 SELL), IBO captures the overall institutional head-to-head verdict (7–2 matrix metrics and 2–1 across the 6 pillars) due to superior fundamental profitability (-12621.0% vs. -960.8% operating margin) and revenue trajectory (+16.7% vs. -72.2% YoY).
- Technical & Structure Timing Caution: OSRH is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.4); meanwhile IBO trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About OSRH vs IBO
OSRH
OSR Holdings, Inc. Common Stock
$0.12
-53.4% 1D
Market Cap
$8.8M
TTM Revenue
$1.8M
Forward P/E
N/M
Beta / 30D Vol
0.57β · 390% Vol
Unified Composite Score
45.0
HOLD
Tech 33.0
Fund 46.0
Flow 50.0
Mom 60.0
Weinstein Technical Phase
Markdown · Sell / avoid
IBO
Head-to-Head Winner
Impact BioMedical, Inc.
$4.91
-4.47% 1D
Market Cap
$44.4M
TTM Revenue
$2.6M
Forward P/E
N/M
Beta / 30D Vol
-6.72β · 120% Vol
Unified Composite Score
36.8
SELL
Tech 15.0
Fund 32.0
Flow 50.0
Mom 40.0
Weinstein Technical Phase
Markup · Hold / add on dips
6-Pillar Scorecard Institutional Category Breakdown (OSRH 1 – 2 IBO)
1. Valuation Multiples
Tie
Forward P/E
N/M
N/M
Trailing P/E
N/M
0.4x
PEG Ratio
N/M
N/M
EV / Revenue
6.7x
17.4x
2. Growth & Scale
IBO
Revenue Growth (YoY)
-72.2%
+16.7%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$1.8M
$2.6M
Market Cap
$8.8M
$44.4M
3. Profitability & Quality
OSRH
Gross Margin
33.4%
N/A
Operating Margin
-960.8%
-12621.0%
Net Profit Margin
0.0%
4247.4%
Return on Equity (ROE)
-11.3%
71.2%
4. Balance Sheet & Cash Flow
IBO
Cash Generation (TTM)
-$5.4M
-$284M EBITDA
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$3.4M Net Debt (0.05x D/E)
$1.18 Book/Sh · 71.2% ROE
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
Tie
Options Structure Phase
UNCLASSIFIED
UNCLASSIFIED
Current IV / %ile
N/A (N/A)
N/A (N/A)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Markdown
NEUTRAL · Markup
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
High-Margin Pricing Power Moat
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: OSRH (2) vs IBO (7)| Institutional Metric | OSRH | IBO | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $8.8M | $44.4M | IBO | |
| Trailing P/E Ratio | N/M | 0.4x | IBO | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | -72.2% | +16.7% | IBO | |
| Operating Margin (TTM) | -960.8% | -12621.0% | OSRH | |
| Net Profit Margin | 0.0% | 4247.4% | IBO | |
| Return on Equity (ROE) | -11.3% | 71.2% | IBO | |
| 52-Week Range Position | 3% ($0–$1) | 67% ($0–$7) | IBO | |
| Beta / 30D Volatility | 0.57β · 390% Vol | -6.72β · 120% Vol | IBO | |
| Unified Institutional Score | 45.0 / 100 (HOLD) | 36.8 / 100 (SELL) | OSRH | |
| Trailing 12M Revenue (USD) | $1.8M | $2.6M | Scale | |
| Gross Profit Margin (TTM) | 33.4% | N/A | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 6.7x EV/Rev | N/M PEG · 17.4x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$5.4M ($3.4M Net Debt (0.05x D/E)) | -$284M EBITDA ($1.18 Book/Sh · 71.2% ROE) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
IBO +79.63 pp
3M Horizon
IBO +66.34 pp
6M Horizon
IBO +77.98 pp
1Y Horizon
IBO +69.62 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | OSRH Revenue | IBO Revenue | OSRH Op. Margin | IBO Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2022 | N/A | $0M | N/A | -6808.0% | IBO |
| FY2024 | $0M | N/A | -331.2% | N/A | OSRH |
| FY2025 | $0M | $0M | -631.0% | -13381.2% | OSRH |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
OSRH
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact OSRH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
IBO
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact IBO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
OSRH Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
IBO Moat Profile
High-Margin Pricing Power Moat
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ OSRH vs IBO Key Questions & Quantitative Answers
As of Nov 16, 2026, Impact BioMedical, Inc. (IBO) is the stronger overall head-to-head candidate over OSR Holdings, Inc. (OSRH) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow). OSRH carries a Unified Composite Score of 45.0/100 (HOLD) at $0.12 (N/M Forward P/E, -960.8% operating margin), whereas IBO carries 36.8/100 (SELL) at $4.91 (N/M Forward P/E, -12621.0% operating margin). Composite vs. Pillar Nuance: While OSRH currently prints a higher short-term Unified Composite Score (45.0/100 HOLD vs. IBO 36.8/100 SELL), IBO captures the overall institutional head-to-head verdict (7–2 matrix metrics and 2–1 across the 6 pillars) due to superior fundamental profitability (-12621.0% vs. -960.8% operating margin) and revenue trajectory (+16.7% vs. -72.2% YoY). Technical & Structure Timing Caution: OSRH is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.4); meanwhile IBO trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
IBO leads the Growth & Scale pillar: OSRH posts -72.2% YoY revenue growth and +0.0% YoY earnings growth on $1.8M TTM revenue (33.4% gross margin, -960.8% operating margin), compared with IBO at +16.7% YoY revenue growth and +0.0% YoY earnings growth on $2.6M TTM revenue (N/A gross margin, -12621.0% operating margin). Across the 3-period historical trajectory (FY2022 to FY2025), OSRH cumulative revenue shifted N/A while IBO shifted N/A. In operating R&D and SG&A reinvestment, OSRH deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for IBO.
OSRH and IBO trade at balanced relative valuation multiples. OSRH trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 6.7x EV/Revenue (unreported FCF margin), whereas IBO trades at N/M Forward P/E, 0.4x Trailing P/E, N/M PEG, and 17.4x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against OSRH (-11.3% ROE) versus IBO (71.2% ROE) capital efficiency.
In options market volatility and institutional positioning, OSRH carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.57β · 390% Vol realized risk). By comparison, IBO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-6.72β · 120% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
IBO vs OSRH · Reverse Pair
OSRH vs ASBP
· Sector Peer
IBO vs PLRZ
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking
VRT vs ETN
· AI Power & Thermal